MAP2K1 P124Q
|
Melanoma
|
MAP2K1 P124Q
|
Melanoma
|
trametinib Resistant: C3 – Early Trials
|
trametinib Resistant: C3 – Early Trials
|
MAP2K1 P124Q
|
Melanoma
|
MAP2K1 P124Q
|
Melanoma
|
dabrafenib Sensitive: C3 – Early Trials
|
dabrafenib Sensitive: C3 – Early Trials
|
MAP2K1 P124Q
|
Melanoma
|
MAP2K1 P124Q
|
Melanoma
|
VTX-11e Sensitive: D – Preclinical
|
VTX-11e Sensitive: D – Preclinical
|